1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Follicular Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Chemotherapy
  • 1.2.3 Radiotherapy
  • 1.2.4 Monoclonal Antibodies
  • 1.2.5 Stem Cell Transplantation
• 1.3 Market by Application
  • 1.3.1 Global Follicular Lymphoma Treatment Market Share by Application: 2020 VS 2026
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Follicular Lymphoma Treatment Market Perspective (2015-2026)
• 2.2 Global Follicular Lymphoma Treatment Growth Trends by Regions
  • 2.2.1 Follicular Lymphoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Follicular Lymphoma Treatment Historic Market Share by Regions (2015-2020)
  • 2.2.3 Follicular Lymphoma Treatment Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Follicular Lymphoma Treatment Players by Market Size
  • 3.1.1 Global Top Follicular Lymphoma Treatment Players by Revenue (2015-2020)
  • 3.1.2 Global Follicular Lymphoma Treatment Revenue Market Share by Players (2015-2020)
• 3.2 Global Follicular Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Follicular Lymphoma Treatment Revenue
• 3.4 Global Follicular Lymphoma Treatment Market Concentration Ratio
  • 3.4.1 Global Follicular Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Treatment Revenue in 2019
• 3.5 Key Players Follicular Lymphoma Treatment Area Served
• 3.6 Key Players Follicular Lymphoma Treatment Product Solution and Service
• 3.7 Date of Enter into Follicular Lymphoma Treatment Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Follicular Lymphoma Treatment Breakdown Data by Type (2015-2026)

• 4.1 Global Follicular Lymphoma Treatment Historic Market Size by Type (2015-2020)
• 4.2 Global Follicular Lymphoma Treatment Forecasted Market Size by Type (2021-2026)

5 Follicular Lymphoma Treatment Breakdown Data by Application (2015-2026)

• 5.1 Global Follicular Lymphoma Treatment Historic Market Size by Application (2015-2020)
• 5.2 Global Follicular Lymphoma Treatment Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Follicular Lymphoma Treatment Market Size (2015-2026)
• 6.2 North America Follicular Lymphoma Treatment Market Size by Type (2015-2020)
• 6.3 North America Follicular Lymphoma Treatment Market Size by Application (2015-2020)
• 6.4 North America Follicular Lymphoma Treatment Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Follicular Lymphoma Treatment Market Size (2015-2026)
• 7.2 Europe Follicular Lymphoma Treatment Market Size by Type (2015-2020)
• 7.3 Europe Follicular Lymphoma Treatment Market Size by Application (2015-2020)
• 7.4 Europe Follicular Lymphoma Treatment Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Follicular Lymphoma Treatment Market Size (2015-2026)
• 8.2 China Follicular Lymphoma Treatment Market Size by Type (2015-2020)
• 8.3 China Follicular Lymphoma Treatment Market Size by Application (2015-2020)
• 8.4 China Follicular Lymphoma Treatment Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Follicular Lymphoma Treatment Market Size (2015-2026)
• 9.2 Japan Follicular Lymphoma Treatment Market Size by Type (2015-2020)
• 9.3 Japan Follicular Lymphoma Treatment Market Size by Application (2015-2020)
• 9.4 Japan Follicular Lymphoma Treatment Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Follicular Lymphoma Treatment Market Size (2015-2026)
• 10.2 Southeast Asia Follicular Lymphoma Treatment Market Size by Type (2015-2020)
• 10.3 Southeast Asia Follicular Lymphoma Treatment Market Size by Application (2015-2020)
• 10.4 Southeast Asia Follicular Lymphoma Treatment Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Boehringer Ingelheim GmbH
  • 11.1.1 Boehringer Ingelheim GmbH Company Details
  • 11.1.2 Boehringer Ingelheim GmbH Business Overview
  • 11.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Introduction
  • 11.1.4 Boehringer Ingelheim GmbH Revenue in Follicular Lymphoma Treatment Business (2015-2020))
  • 11.1.5 Boehringer Ingelheim GmbH Recent Development
• 11.2 Bristol-Myers Squibb Company
  • 11.2.1 Bristol-Myers Squibb Company Company Details
  • 11.2.2 Bristol-Myers Squibb Company Business Overview
  • 11.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Introduction
  • 11.2.4 Bristol-Myers Squibb Company Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.2.5 Bristol-Myers Squibb Company Recent Development
• 11.3 Celgene Corporation
  • 11.3.1 Celgene Corporation Company Details
  • 11.3.2 Celgene Corporation Business Overview
  • 11.3.3 Celgene Corporation Follicular Lymphoma Treatment Introduction
  • 11.3.4 Celgene Corporation Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.3.5 Celgene Corporation Recent Development
• 11.4 Celldex Therapeutics, Inc.
  • 11.4.1 Celldex Therapeutics, Inc. Company Details
  • 11.4.2 Celldex Therapeutics, Inc. Business Overview
  • 11.4.3 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Introduction
  • 11.4.4 Celldex Therapeutics, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.4.5 Celldex Therapeutics, Inc. Recent Development
• 11.5 Celltrion, Inc.
  • 11.5.1 Celltrion, Inc. Company Details
  • 11.5.2 Celltrion, Inc. Business Overview
  • 11.5.3 Celltrion, Inc. Follicular Lymphoma Treatment Introduction
  • 11.5.4 Celltrion, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.5.5 Celltrion, Inc. Recent Development
• 11.6 Cellular Biomedicine Group, Inc.
  • 11.6.1 Cellular Biomedicine Group, Inc. Company Details
  • 11.6.2 Cellular Biomedicine Group, Inc. Business Overview
  • 11.6.3 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Introduction
  • 11.6.4 Cellular Biomedicine Group, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.6.5 Cellular Biomedicine Group, Inc. Recent Development
• 11.7 Coherus BioSciences, Inc.
  • 11.7.1 Coherus BioSciences, Inc. Company Details
  • 11.7.2 Coherus BioSciences, Inc. Business Overview
  • 11.7.3 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Introduction
  • 11.7.4 Coherus BioSciences, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.7.5 Coherus BioSciences, Inc. Recent Development
• 11.8 CTI BioPharma Corp.
  • 11.8.1 CTI BioPharma Corp. Company Details
  • 11.8.2 CTI BioPharma Corp. Business Overview
  • 11.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Introduction
  • 11.8.4 CTI BioPharma Corp. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.8.5 CTI BioPharma Corp. Recent Development
• 11.9 Curis, Inc.
  • 11.9.1 Curis, Inc. Company Details
  • 11.9.2 Curis, Inc. Business Overview
  • 11.9.3 Curis, Inc. Follicular Lymphoma Treatment Introduction
  • 11.9.4 Curis, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.9.5 Curis, Inc. Recent Development
• 11.10 Dynavax Technologies Corporation
  • 11.10.1 Dynavax Technologies Corporation Company Details
  • 11.10.2 Dynavax Technologies Corporation Business Overview
  • 11.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Introduction
  • 11.10.4 Dynavax Technologies Corporation Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 11.10.5 Dynavax Technologies Corporation Recent Development
• 11.11 Eisai
  • 10.11.1 Eisai Company Details
  • 10.11.2 Eisai Business Overview
  • 10.11.3 Eisai Follicular Lymphoma Treatment Introduction
  • 10.11.4 Eisai Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.11.5 Eisai Recent Development
• 11.12 EpiZyme, Inc.
  • 10.12.1 EpiZyme, Inc. Company Details
  • 10.12.2 EpiZyme, Inc. Business Overview
  • 10.12.3 EpiZyme, Inc. Follicular Lymphoma Treatment Introduction
  • 10.12.4 EpiZyme, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.12.5 EpiZyme, Inc. Recent Development
• 11.13 F. Hoffmann-La Roche Ltd.
  • 10.13.1 F. Hoffmann-La Roche Ltd. Company Details
  • 10.13.2 F. Hoffmann-La Roche Ltd. Business Overview
  • 10.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Introduction
  • 10.13.4 F. Hoffmann-La Roche Ltd. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.13.5 F. Hoffmann-La Roche Ltd. Recent Development
• 11.14 Genentech, Inc.
  • 10.14.1 Genentech, Inc. Company Details
  • 10.14.2 Genentech, Inc. Business Overview
  • 10.14.3 Genentech, Inc. Follicular Lymphoma Treatment Introduction
  • 10.14.4 Genentech, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.14.5 Genentech, Inc. Recent Development
• 11.15 Gilead Sciences, Inc.
  • 10.15.1 Gilead Sciences, Inc. Company Details
  • 10.15.2 Gilead Sciences, Inc. Business Overview
  • 10.15.3 Gilead Sciences, Inc. Follicular Lymphoma Treatment Introduction
  • 10.15.4 Gilead Sciences, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.15.5 Gilead Sciences, Inc. Recent Development
• 11.16 GlaxoSmithKline Plc
  • 10.16.1 GlaxoSmithKline Plc Company Details
  • 10.16.2 GlaxoSmithKline Plc Business Overview
  • 10.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Introduction
  • 10.16.4 GlaxoSmithKline Plc Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.16.5 GlaxoSmithKline Plc Recent Development
• 11.17 Hutchison MediPharma Limited
  • 10.17.1 Hutchison MediPharma Limited Company Details
  • 10.17.2 Hutchison MediPharma Limited Business Overview
  • 10.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Introduction
  • 10.17.4 Hutchison MediPharma Limited Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.17.5 Hutchison MediPharma Limited Recent Development
• 11.18 Immune Design Corp.
  • 10.18.1 Immune Design Corp. Company Details
  • 10.18.2 Immune Design Corp. Business Overview
  • 10.18.3 Immune Design Corp. Follicular Lymphoma Treatment Introduction
  • 10.18.4 Immune Design Corp. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.18.5 Immune Design Corp. Recent Development
• 11.19 ImmunoGen, Inc.
  • 10.19.1 ImmunoGen, Inc. Company Details
  • 10.19.2 ImmunoGen, Inc. Business Overview
  • 10.19.3 ImmunoGen, Inc. Follicular Lymphoma Treatment Introduction
  • 10.19.4 ImmunoGen, Inc. Revenue in Follicular Lymphoma Treatment Business (2015-2020)
  • 10.19.5 ImmunoGen, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Global Follicular Lymphoma Treatment Scope and Market Size
Follicular Lymphoma Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Follicular Lymphoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation

Market segment by Application, split into
Hospital
Clinic
Others

Based on regional and country-level analysis, the Follicular Lymphoma Treatment market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Follicular Lymphoma Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.